# Multicenter Study of Pharmacokinetic-Guided Docetaxel in Breast Cancer Patients Receiving Docetaxel and Cyclophosphamide

> **NCT02502864** · PHASE4 · COMPLETED · sponsor: **H. Lee Moffitt Cancer Center and Research Institute** · enrollment: 9 (actual)

## Conditions studied

- Breast Cancer
- Breast Cancer Female

## Interventions

- **DRUG:** Standard of Care: Docetaxel
- **DRUG:** Standard of Care: Cyclophosphamide
- **OTHER:** Function Assessment of Cancer Therapy (FACT) Surveys

## Key facts

- **NCT ID:** NCT02502864
- **Lead sponsor:** H. Lee Moffitt Cancer Center and Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-02-09
- **Primary completion:** 2017-09-29
- **Final completion:** 2019-01-31
- **Target enrollment:** 9 (ACTUAL)
- **Last updated:** 2020-09-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02502864

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02502864, "Multicenter Study of Pharmacokinetic-Guided Docetaxel in Breast Cancer Patients Receiving Docetaxel and Cyclophosphamide". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT02502864. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*